Treatment of myelosuppression

一种骨髓抑制、治疗方案的技术，应用在治疗、放射疗法、含有效成分的医用配制品等方向，能够解决降低治疗剂量、治疗方案副作用、延迟等问题

Inactive Publication Date: 2018-09-07
CANTEX PHARMA INC
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Neutropenia can be caused by a number of different causes, from birth defects to viral infections, but in this context neutropenia is often seen as a side effect of treatment regimens
Neutropenia is a common side effect in patients treated with antineoplastic drugs for cancer, putting patients at risk of serious or even life-threatening infections and delaying treatment and / or necessitating lower treatment doses, resulting in reduced efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of myelosuppression
  • Treatment of myelosuppression
  • Treatment of myelosuppression

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0249] 6.2 Example 2: ODSH, a heparanoid that interacts with PF4, enhances the efficacy of carboplatin in a mouse xenograft model of human ovarian cancer

[0250] This example demonstrates that adjuvant administration of ODSH enhances the efficacy of carboplatin against human ovarian tumors grown as xenografts in athymic nude mice.

[0251] Materials & Methods ODSH (50 mg / mL stock concentration) was prepared by Pyramid Laboratories, Inc. and stored at room temperature until use. As described further below, ODSH can be administered either intravenously (IV) at a dose of 48 mg / kg and a volume of 10 mL / kg or subcutaneously (SC) at a dose of 24 mg / kg and a volume of 5 mL / kg. Carboplatin obtained from clinical suppliers was stored at 4°C until use. Carboplatin was administered by intraperitoneal injection (IP) at a dose of 80 mg / kg and a volume of 10 mL / kg. Saline solution (0.9% NaCl) was used as a vehicle control for ODSH and was administered by the same route and in the same vo...

Embodiment 3

[0267] 6.3 Example 3: ODSH, a heparanoid that interacts with PF4, alleviates thrombocytopenia and neutropenia, induces thrombopoiesis and neutrophil production and reduces exposure to chemotherapy regimens with myelosuppressive side effects Patient's systemic symptoms

[0268] In an unblinded clinical trial, patients diagnosed with metastatic pancreatic cancer were treated with ODSH as gemcitabine and nab-paclitaxel ( Adjuvant therapy with albumin-bound paclitaxel).

[0269] Inclusion criteria Male and non-pregnant, non-lactating female patients aged 18 to 75 years with histologically confirmed metastatic adenocarcinoma participated in the trial. Other inclusion criteria were: presence of at least one metastatic tumor (measurable by conventional techniques or CT scan), serum CA 19-9 measurement greater than 2 times the upper limit of normal, no local targeted therapy within six months of participation in the trial Radiotherapy or chemotherapy for advanced disease, absolute ...

Embodiment 4

[0321] 6.4 Example 4: ODSH relieves thrombocytopenia associated with the treatment of acute myelogenous leukemia (AML)

[0322] The clinical trial was conducted to confirm the therapeutic advantages of ODSH administered as adjuvant induction and consolidation therapy and adjunctive subsequent treatment of allogeneic or autologous bone marrow transplantation in acute myeloid leukemia (AML). Subjects included in this experiment were those diagnosed with AML who were receiving induction and consolidation therapy. Subjects were randomly assigned to the control group (receiving induction and consolidation therapy only) or the treatment group (receiving adjuvant ODSH). ODSH was administered by continuous infusion (0.375 mg / kg / hr). Subjects in each group of the experiment were evaluated for platelet counts and the need for platelet transfusions. Other parameters assessed included measuring circulating levels of PF4 and granulocyte recovery.

[0323] Results were obtained demonstra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.

Description

[0001] This application is based on a divisional application of a patent application with an application date of March 13, 2013, an application number of 201380036055.1 (PCT / US2013 / 031053), and an invention title of "Treatment of Bone Marrow Suppression". [0002] 1. Cross references to related applications [0003] This application is based on 35 U.S.C. § 119(e) requiring U.S. provisional applications 61 / 724,836 (filed November 9, 2012); 61 / 702,207 (filed September 17, 2012); 61 / 678,053 (filed July 2012 61 / 668,709 (filed 6 July 2012); 61 / 664,611 (filed 26 June 2012); 61 / 653,362 (filed 30 May 2012); 61 / 648,043 (filed May 16, 2012); 61 / 644,623 (filed May 9, 2012); and 61 / 644,556 (filed May 9, 2012), the entire contents of which are incorporated herein by reference . 2. Background technology [0004] Platelets play a key role in the coagulation mechanism. Thrombocytopenia below a certain level results in thrombocytopenia, which can be triggered by a range of clinical condit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/727A61K45/06A61K31/7068A61K31/337A61P35/00A61P35/02
CPCA61K31/727A61K45/06A61P35/02A61P7/00A61P7/04A61K35/28A61K39/395A61N5/00
Inventor S.马库斯
Owner CANTEX PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap